What do we offer?
- Detection of genes involved in predisposition to : Dyslipidemia - Acute myocardial infarction
- Counselling by a specialist before and after the analysis
- Sample type: Collection of saliva through an oral swab
- Results in: 14 days*
- € 330 **
* Labour days counting from reception of the sample at the laboratory.
** Shipping charges included in peninsular Spain. Not included in Islands.
Why should you request this service?
What is the purpose of this analysis?>
To prevent the development of heart disease. At least 80% of premature deaths from heart disease and stroke could be prevented with regular predictive tests that prevent the need for lifestyle changes, healthy eating and regular physical activity.
To make you aware of the risk you run of suffering from ischemic coronary artery disease and thus giving you the opportunity to prevent its appearance with healthy lifestyles and personalized treatments.
Should you do it?>
You have a family history of dyslipidemia, diabetes, hypertension, obesity.
You suffer from diabetes, high blood pressure or obesity.
You are a man over 50 years old.
How does it work?
Choose your analysis and a healthcare professional will contact you in 48 hours.
Receive a sample collector kit at home that will be picked up by a courier.
One of our partner labs makes the analysis.
Your healthcare professional presents your results by videoconference.
Do you need more information?
What are the genes studied and what does it mean?>
GENE OMIM or reference RELATED DISEASE SYNDROME ACE 106180 Diseases of the coronary arteries and cardiovascular diseases Risk of acute myocardial infarction
Risk of hypertension
APOA5 606368 Risk of hypertriglyceridaemia APOC3 107720 Risk of hypertriglyceridaemia APOE 107741 Cardiovascular diseases
How to interpret the results?>
POSITIVE NEGATIVE Gene ACE: POLYMORPHISME IVS16-407ins(289nt)
Gene APOA5: POLYMORPHISME c.-73-571C>T
Gene APOC3: POLYMORPHISME c.*40G>C
Gene APOE: POLYMORPHISME *E3/*E4
No genetic variants predisposing to the disease have been detected. Increased risk Moderate risk
Sensitivity and Specificity>
The analysis of this gene is carried out using the PCR (Polymerase Chain Reaction) technique. Moreover, the results are studied by direct sequencing and subsequent capillary electrophoresis. These molecular biology techniques are commonly used in the field of molecular genetics and exhibit high sensitivity and specificity when using specific primers for each analyzed polymorphism. The reliability of our genetic studies is close to 100%, we apply quality processes certified by competent national and international organizations.
- Cordero, A., et al. Situación actual de la dislipemia en España: La visión del cardiólogo. Revista Española de Cardiología Suplementos, vol. 15 issue Supl.A (2015) pp: 2-7 Published by Elsevier; doi: 10.1016/S1131-3587(15)70117-2.
- Nichols M, et al. European Cardiovascular Disease Statistics 2012. European Heart Network, Brussels and European Society of Cardiology. Sophia Antipolis. 2012.
- Cambien, F., et al. Familial resemblance of plasma angiotensin-converting enzyme level: the Nancy study. Am. J. Hum. Genet. 43: 774-780, 1988
- Frikke-Schmidt, R. et al. Subsets of SNPs define rare genotype classes that predict ischemic heart disease. Hum. Genet. 120: 865-877, 2007.
- Lu Y y cols. Exploring genetic determinants of plasma total cholesterol levels and their predictive value in a longitudinal study. Atherosclerosis. 2010 Nov;213(1):200-5.
- Ding Y, Zhu MA, Wang ZX, Zhu J, Feng JB, Li DS. Associations of polymorphisms in the apolipoprotein APOA1-C3-A5 gene cluster with acute coronary syndrome. J Biomed Biotechnol. 2012;2012:509420.
- Abd El-Aziz TA, Mohamed RH, Hashem RM. Association of lipoprotein lipase and apolipoprotein C-III genes polymorphism with acute myocardial infarction in diabetic patients. Mol Cell Biochem. 2011 Aug;354(1-2):141-50.
- Evans D, Bode A, von der Lippe G, Beil FU, Mann WA. Cerebrovascular atherosclerosis in type III hyperlipidemia is modulated by variation in the apolipoprotein A5 gene. Eur J Med Res. 2011 Feb 24;16(2):79-84.
- Yamada Y y cols. Prediction of genetic risk for dyslipidemia. Genomics. 2007 Nov;90(5):551-8. Epub 2007 Oct 4.
- Stancáková A, Baldaufová L, Javorský M, Kozárová M, Salagovic J, Tkác I. Effect of gene polymorphisms on lipoprotein levels in patients with dyslipidemia of metabolic syndrome. Physiol Res. 2006;55(5):483-90. Epub 2005 Dec 12.